Cedomir Stamenkovic

Cedomir Stamenkovic

Auto-generated profile, based on publicly available information

Cedomir Stamenkovic

Development, Aging, and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Science Advances
Verified
Journal Article
Open access
UHUlalume Hernández-Arciga
Ulalume Hernández-Arciga
CSCeda Stamenkovic
Ceda Stamenkovic
SYShweta Yadav
Shweta Yadav
CNChiara Nicoletti
Chiara Nicoletti
WAWafaa N. Albalawy
Wafaa N. Albalawy
APAndrey A. Parkhitko
Andrey A. Parkhitko
Aging is associated with dysregulated methionine metabolism and increased levels of enzymes in the tyrosine degradation pathway (TDP). To investigate the efficacy of targeting either methionine metabolism or the TDP for healthspan improvement in advanced age, we initiated dietary MetR or TDP inhibition in 18-month-old C57BL/6J mice. MetR significantly improved neuromuscular function, metabolic health, lung function, and frailty. In addition, we confirmed improved neuromuscular function from dietary MetR in 5XFAD mice, whose weight was not affected by MetR. We did not observe benefits with TDP inhibition. Single-nucleus RNA and ATAC sequencing of muscle revealed cell type–specific responses to MetR, although MetR did not significantly affect mouse aging epigenetic clock markers. Similarly, an 8-week MetR intervention in a human trial (NCT04701346) showed no significant impact on epigenetic clocks. The observed benefits from late-life MetR provide translational rationale to develop MetR mimetics as an antiaging intervention.

10 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLuca Caputo
Luca Caputo
CSCedomir Stamenkovic
Cedomir Stamenkovic
MTMatthew T. Tierney
Matthew T. Tierney
MFMaria Sofia Falzarano
Maria Sofia Falzarano
RBRhonda Bassel-Duby
Rhonda Bassel-Duby
ASAlessandra Sacco
Alessandra Sacco
Summary: Generation of in vitro induced pluripotent cells (hiPSCs)-derived skeletal muscle progenitor cells (SMPCs) holds great promise for regenerative medicine for skeletal muscle wasting diseases, as for example Duchenne Muscular Dystrophy (DMD). Multiple approaches, involving ectopic expression of key regulatory myogenic genes or small molecules cocktails, have been described by different groups to obtain SMPC towards cell-transplantation in vivo as a therapeutic approach to skeletal muscle diseases. However, hiPSCs-derived SMPC generated using transgene-free protocols are usually obtained in a low amount and resemble a more embryonal/fetal stage of differentiation. Here we demonstrate that modulation of the JAK2/STAT3 signaling pathway during an in vitro skeletal muscle differentiation protocol, increases the yield of PAX7+ and CD54+ SMPCs and drive them to a post- natal maturation stage, in both human ES and patient-derived iPSCs. Importantly, upon removal of the inhibition from the cultures, the obtained SMPCs are able to differentiate into multinucleated myotubes in vitro. These findings reveal that modulation of the JAK2/STAT3 signaling pathway is a potential therapeutic avenue to generate SMPCs in vitro with increase potential for cell-therapy approaches.